Pathology & Oncology Research

, Volume 18, Issue 2, pp 263–270 | Cite as

CDH13 and FLBN3 Gene Methylation are Associated with Poor Prognosis in Colorectal Cancer

  • Zhu Wang
  • Xin Yuan
  • Nanlin Jiao
  • Hui Zhu
  • Youwei Zhang
  • Jiandong TongEmail author


The aim of this study was to identify potential epigenetic prognostic biomarkers for colorectal cancer (CRC) in the Chinese population. The methylation status of five tumor suppressor genes (CDH13, DLEC1, FBLN3, hMHL1 and RUNX3) was determined using manual microdissection followed by methylation-specific PCR in 85 paired CRC specimens and adjacent normal tissue. The results showed that methylation frequencies in cancerous tissues were 31.8% for CDH13, 37.6% for DLEC1, 38.8% for FBLN3, 22.4% for hMHL1 and 27.1% for RUNX3, all of which were significantly higher than in corresponding normal tissue. Furthermore, CDH13 methylation was associated with poor differentiation (P = 0.019) and tended to be predominant in advanced stages (P = 0.084); FBLN3 methylation was associated with advanced stages (P = 0.027) and lymph node metastasis (P = 0.029). Accordingly, the methylation status of CDH13 (P = 0.022), FBLN3 (P = 0.008), CDH13 and/or FBLN3 (P = 0.001) predicted adverse overall survival in CRC, while hMHL1 methylation showed a protective role in survival (P = 0.046). Cox proportional hazard models further indicated that CDH13 and/or FBLN3 methylation, but not that of hMHL1, was an independent prognostic factor for CRC. In conclusion, we found CDH13 and FBLN3 gene methylation are potential biomarkers for poor prognosis in CRC.


Colorectal cancer Methylation Prognosis Microdissection 



Colorectal cancer


Tumor suppressor genes




Deleted in lung and esophageal cancer 1




mutL homolog 1


Runt-related transcription factor 3


Methylation-specific polymerase chain reaction



We are grateful for the participation of our patients and healthy donors, without which our study would not have been possible. The valuable help from the Departments of Pathology of Yijishan Hospital is also greatly appreciated.


  1. 1.
    Saif MW, Chu E (2010) Biology of colorectal cancer. Cancer J 16:196–201PubMedCrossRefGoogle Scholar
  2. 2.
    Asghar U, Hawkes E, Cunningham D (2010) Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer 9:274–281PubMedCrossRefGoogle Scholar
  3. 3.
    Lopez J, Percharde M, Coley HM et al (2009) The context and potential of epigenetics in oncology. Br J Cancer 100:571–577PubMedCrossRefGoogle Scholar
  4. 4.
    Lesche R, Eckhardt F (2007) DNA methylation markers: a versatile diagnostic tool for routine clinical use. Curr Opin Mol Ther 9:222–230PubMedGoogle Scholar
  5. 5.
    Zhang Y, Song H, Miao Y et al (2010) Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci 101:934–940PubMedCrossRefGoogle Scholar
  6. 6.
    Ogino S, Nosho K, Kirkner GJ et al (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58:90–96PubMedCrossRefGoogle Scholar
  7. 7.
    Kim MS, Lee J, Sidransky D (2010) DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 29:181–206PubMedCrossRefGoogle Scholar
  8. 8.
    Miladi-Abdennadher I, Abdelmaksoud-Damak R, Ayadi L et al (2010) Hypermethylation of RARβ2 correlates with high COX-2 expression and poor prognosis in patients with colorectal carcinoma. Tumour Biol 31:503–511PubMedCrossRefGoogle Scholar
  9. 9.
    Sirivatanauksorn Y, Sirivatanauksorn V, Bhattacharya S et al (1999) Evolution of genetic abnormalities in hepatocellular carcinomas demonstrated by DNA fingerprinting. J Pathol 189:344–350PubMedCrossRefGoogle Scholar
  10. 10.
    Seng TJ, Currey N, Cooper WA et al (2008) DLEC1 and hMHL1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 99:375–382PubMedCrossRefGoogle Scholar
  11. 11.
    Yue W, Dacic S, Sun Q et al (2007) Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 13:4336–4344PubMedCrossRefGoogle Scholar
  12. 12.
    Zhang Y, Wang R, Song H et al (2011) Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 303:21–28PubMedCrossRefGoogle Scholar
  13. 13.
    Dietrich D, Lesche R, Tetzner R et al (2009) Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues. J Histochem Cytochem 57:477–489PubMedCrossRefGoogle Scholar
  14. 14.
    Yang S, Nan Y, Tian Y et al (2008) Study of distinct protein profiles for early diagnosis of NSCLC using LCM and SELDI-TOF-MS. Med Oncol 25:380–386PubMedCrossRefGoogle Scholar
  15. 15.
    Xu XL, Yu J, Zhang HY et al (2004) Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 10:3441–3454PubMedGoogle Scholar
  16. 16.
    Barault L, Charon-Barra C, Jooste V et al (2008) Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 68:8541–8546PubMedCrossRefGoogle Scholar
  17. 17.
    Aoyagi H, Iida S, Uetake H et al (2011) Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis. Oncol Rep 25:789–794PubMedGoogle Scholar
  18. 18.
    Hibi K, Nakayama H, Kodera Y et al (2004) CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer. Br J Cancer 90:1030–1033PubMedCrossRefGoogle Scholar
  19. 19.
    Ying J, Poon FF, Yu J et al (2009) DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer 100:663–669PubMedCrossRefGoogle Scholar
  20. 20.
    Nishio M, Sakakura C, Nagata T et al (2010) RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Anticancer Res 30:2673–2682PubMedGoogle Scholar
  21. 21.
    Fujita H, Kato J, Horii J et al (2007) Decreased expression of hhMHL1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells. Oncol Rep 18:1129–1137PubMedGoogle Scholar
  22. 22.
    de Vega S, Iwamoto T, Yamada Y (2009) Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 66:1890–1902PubMedCrossRefGoogle Scholar
  23. 23.
    Albig AR, Neil JR, Schiemann WP (2006) Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 66:2621–2629PubMedCrossRefGoogle Scholar
  24. 24.
    Sadr-Nabavi A, Ramser J, Volkmann J et al (2009) Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 124:1727–1735PubMedCrossRefGoogle Scholar
  25. 25.
    Wang R, Zhang YW, Chen LB (2010) Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma. Lung Cancer 69:239–244PubMedCrossRefGoogle Scholar
  26. 26.
    Nomoto S, Kanda M, Okamura Y et al (2010) Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol 17:923–932PubMedCrossRefGoogle Scholar
  27. 27.
    Brim H, Mokarram P, Naghibalhossaini F et al (2008) Impact of BRAF, hMHL1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer 7:68PubMedCrossRefGoogle Scholar
  28. 28.
    Noda H, Kato Y, Yoshikawa H et al (2005) Microsatellite instability caused by hhMHL1 promoter methylation increases with tumor progression in right-sided sporadic colorectal cancer. Oncology 69:354–362PubMedCrossRefGoogle Scholar
  29. 29.
    Imai K, Yamamoto H (2008) Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673–680PubMedCrossRefGoogle Scholar
  30. 30.
    Poynter JN, Siegmund KD, Weisenberger DJ, Colon Cancer Family Registry Investigators et al (2008) Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 17:3208–3215PubMedCrossRefGoogle Scholar
  31. 31.
    Arai T, Kasahara I, Sawabe M et al (2010) Role of methylation of the hhMHL1 gene promoter in the development of gastric and colorectal carcinoma in the elderly. Geriatr Gerontol Int 10:S207–S212PubMedCrossRefGoogle Scholar
  32. 32.
    Ide T, Kitajima Y, Ohtaka K et al (2008) Expression of the hhMHL1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer. Oncol Rep 19:1571–1576PubMedGoogle Scholar
  33. 33.
    Toyota M, Issa JP (1999) CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 9:349–357PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2011

Authors and Affiliations

  • Zhu Wang
    • 1
  • Xin Yuan
    • 1
  • Nanlin Jiao
    • 2
  • Hui Zhu
    • 1
  • Youwei Zhang
    • 1
  • Jiandong Tong
    • 1
    Email author
  1. 1.Department of Oncology, Yangzhou No.1 People’s HospitalThe second Clinical School of Yangzhou UniversityYangzhouChina
  2. 2.Department of Pathology, Yijishan HospitalWannan Medical CollegeWuhuChina

Personalised recommendations